( MENAFN - GlobeNewsWire - Nasdaq) VICTORIA, Seychelles, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Bitget Wallet , a leading Web3 non-custodial wallet, has integrated the HyperEVM testnet, offering users a one-click feature to add the Network to their custom mainnets. Users can now easily access the Hyperliquid ecosystem, participate in its innovative decentralized applications, explore top-tier projects within HyperEVM, and receive test tokens via the Hyperliquid faucet, paving the way for deeper engagement with the ecosystem's DeFi capabilities and improving the overall user experience. This move comes as Hyperliquid's ecosystem continues to gain momentum in the blockchain space. The introduction of HyperEVM is set to significantly expand the use cases of the $HYPE token, which users will now employ for gas fees, as well as for lending, staking, and other DeFi activities. The gas-free trading experience provided by Hyperliquid's DEX is attracting increasing user interest and liquidity, positioning the platform for substantial growth. Additionally, DeFi projects such as lending platforms and automated market makers will go live alongside HyperEVM, improving capital efficiency and expanding the ecosystem's scope. Bitget Wallet's integration with HyperEVM enhances its reputation as a reliable and cutting-edge wallet solution. The platform has continuously added support for new and emerging tokens, allowing users to trade and engage with the latest blockchain assets. By prioritizing easy access to DeFi and decentralized ecosystems, Bitget Wallet continues to offer users a seamless and enhanced experience, ensuring they are equipped to take advantage of the latest market developments. Alvin Kan, COO of Bitget Wallet, shared "At Bitget Wallet, we aim to foster innovation by supporting projects like Hyperliquid that push the boundaries of blockchain technology. Our integration with the HyperEVM testnet reflects our commitment to offering users the tools to participate in the next wave of decentralized finance. By providing early access to HyperEVM and its evolving ecosystem, we are enhancing the value for our community and helping shape the future of Web3, ensuring they are always ahead of the curve in this fast-moving space." About Bitget Wallet Bitget Wallet is the home of Web3, uniting endless possibilities in one non-custodial wallet. With over 40 million users, it offers comprehensive on-chain services, including asset management, instant swaps, rewards, staking, trading tools, live market data, a DApp browser, and an NFT marketplace. Designed for everyone from beginners to advanced traders, it supports mnemonic, MPC, and AA wallet options. With connections to over 100 blockchains, 20,000+ DApps, and 500,000+ tokens, Bitget Wallet enables seamless multi-chain trading across hundreds of DEXs and cross-chain bridges, along with a $300 million protection fund for your digital assets. Experience Bitget Wallet Lite to start your Web3 journey. For more information, visit: Twitter | Telegram | Instagram | YouTube | LinkedIn | TikTok | Discord For media inquiries, please contact ... MENAFN19122024004107003653ID1109014723 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Short Interest in Atos SE (OTCMKTS:AEXAY) Grows By 1,066.7%Tonix Pharmaceuticals Holding Corp. ( NASDAQ:TNXP – Get Free Report )’s stock price was down 2.6% on Thursday . The company traded as low as $0.35 and last traded at $0.38. Approximately 36,840,297 shares were traded during mid-day trading, an increase of 23% from the average daily volume of 30,057,420 shares. The stock had previously closed at $0.39. Wall Street Analyst Weigh In Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Monday, December 23rd. They set a “hold” rating on the stock. Read Our Latest Stock Analysis on TNXP Tonix Pharmaceuticals Price Performance Tonix Pharmaceuticals ( NASDAQ:TNXP – Get Free Report ) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. On average, research analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year. Tonix Pharmaceuticals Company Profile ( Get Free Report ) Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Recommended Stories Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .

None

In a breakthrough advancement in cancer treatment , scientists have developed an innovative approach that can aid in converting colon cancer cells into healthy ones without the need to kill them. This could help minimize the severe side effects from the traditional cancer treatments like chemotherapy that attempt to kill the cancer cells for achieving remission. This astonishing method has been found by the researchers at Korea Advanced Institute of Science and Technology (KAIST) which can potentially prevent cancer recurrence. Traditional cancer therapies like surgery, chemotherapy, and radiation, aim to remove, destroy, or shrink cancerous cells and tumors. Surgery involves physically removing the tumor, while chemotherapy uses powerful drugs to target and kill fast-growing cancer cells throughout the body. Radiation therapy utilizes high-energy beams, like X-rays, to damage the DNA of cancer cells, preventing them from growing and dividing. These treatments are designed to eliminate cancer cells while attempting to minimize damage to surrounding healthy tissues. Professor Kwang-Hyun Cho of the Department of Bio and Brain Engineering said the fact that cancer cells can be converted back to normal cells is an astonishing phenomenon and this study proves that such reversion can be systematically induced. More about the study The study, published in the journal of Advanced Science, introduces a computational framework called BENEIN (single-cell Boolean network inference and control) designed to identify master regulators that control cellular differentiation trajectories, with potential applications for cancer reversion. Traditional cancer therapies are limited, but cancer reversion , which involves reverting cancer cells to a non-malignant state, could offer a new therapeutic approach. To identify key genes involved in this process, BENEIN analyzes single-cell transcriptome data to model gene regulatory networks (GRNs) and determine which master regulators can induce differentiation. In their study, the authors applied BENEIN to human intestinal cells and identified three key regulators—MYB, HDAC2, and FOXA2—that inhibit enterocyte differentiation. When these regulators were simultaneously knocked down in colorectal cancer cells, the cells reverted to a more normal-like state. This approach was also validated in mouse models. The BENEIN framework could be a powerful tool to uncover potential targets for cancer reversion and other biological processes by pinpointing key regulatory molecules that control differentiation pathways. The trouble with conventional cancer treatments is that their focus is on eradicating cancer cells. This faces two key challenges: potential for cancer cells to develop resistance and return, and the collateral damage to healthy cells , which can result in side effects. The new research targets the root cause of cancer development. The research is based on the idea that cancer cells, during their transformation from normal cells, regress along the differentiation trajectory—the process by which normal cells mature into specific functional types. The new approach can transform cancer treatment by targeting the genetic mechanisms underlying cell transformation. This can also help prevent patients from cancer recurrence and the debilitating side effects that come from cancer treatment. Researchers find cancer-related fibroblasts induce drug sensitivity

A deal which could see the Elgin Marbles returned to Greece is “still some distance” away, George Osborne has signalled. The former Tory chancellor, now chairman of the British Museum, suggested Sir Keir Starmer had contributed to a warmer spirit of the negotiations over the famous ancient artworks. Greece has long called for the return of the Marbles, also known as the Parthenon sculptures, and maintains they were illegally removed from Athens’ acropolis during a period of foreign occupation. The British Museum – where they are currently on display – is forbidden by law from giving away any of its artefacts, and the Government has no plans to change the law to permit a permanent move. But under Mr Osborne’s leadership, the museum is negotiating the possibility of a long-term loan of the sculptures, in exchange for rolling exhibitions of famous artworks. No 10 has indicated the Prime Minister is unlikely to stand in the way of such a deal. Speaking on Political Currency, the podcast he hosts alongside former Labour politician Ed Balls, Mr Osborne said the museum was “looking to see if we can come to some arrangement where at some point some of the sculptures are in Athens, where, of course, they were originally sited”. He added: “And in return, Greece lends us some of its treasures, and we made a lot of progress on that, but we’re still some distance from any kind of agreement.” The Greek government has suggested negotiations with the museum have taken a warmer tone since Labour came to power in the summer. Mr Osborne appeared to concur with this view and praised Sir Keir’s hands-off approach, adding: “It is not the same as Rishi Sunak, who refused to see the Greek prime minister, if you remember, he sort of stood him up. “So it seems to me a more sensible and diplomatic way to proceed.” Kyriakos Mitsotakis, the Greek premier, discussed the Elgin Marbles with Sir Keir when they met on Tuesday morning at Downing Street, he said after returning to Athens. Mr Mitsotakis has signalled his government is awaiting developments on the negotiations. A diplomatic spat between the Greek leader and Mr Sunak emerged last year when the then-prime minister refused to meet his counterpart. Mr Mitsotakis had compared splitting the Elgin Marbles from those still in Athens to cutting the Mona Lisa in half. The marble statues came from friezes on the 2,500-year-old Parthenon temple and have been displayed at the British Museum for more than 200 years. They were removed by Lord Elgin in the early 19th century when he was British ambassador to the Ottoman Empire. Some of the remaining temple statues are on display in the purpose-built Acropolis Museum in Athens, and Greece has called for the collections to be reunited.

After 19 mnths, govt resumes public bus transport on 4 routes